Meet the One Million Strong – Kimberly B from Florida

Be a part of One Million Strong and tell us how colorectal cancer has impacted your life! Share your story now!  MEET KIMBERLY Kimberly Bishop, Survivor Osteen, FL KIMBERLY’S STORY I was diagnosed with stage III rectal cancer in February 2007, at age 34.  I was young, fit, and perfectly healthy in every other way.  I share…  Read More

New Trial Looks to Reduce Recurrence and Neuropathy for Stage III Patients

If you are diagnosed with stage III colon cancer, you will probably receive about six months of treatment with FOLFOX after surgery. Research shows that this treatment regimen helps prevent recurrence for some – but not all – patients with stage III colon cancer.  A clinical trial has been launched to answer two questions about this…  Read More

Effexor Reduces Pain from Cold

Colorectal cancer patients getting oxaliplatin quickly learn to avoid cold. Drinks with ice, chilly air, even opening the freezer can produce sudden, sharp pain, burning, or an unpleasant pins and needle feeling in their throat and hands. A small study has found that venlafaxine (Effexor) can completely eliminate acute neurotoxicity from oxaliplatin in about 1 out…  Read More

FOLFOX Effectiveness Not Related to DNA Mismatch Repair or MSI

Colon cancers that are caused by defects in genes that repair damaged DNA don’t respond well to 5-FU treatment after surgery. However, a new analysis of patients treated with FOLFOX (oxaliplatin, leucovorin, and 5-FU) found no differences between patients with deficient mismatch repair tumors and those with normal gene expression. In this small study of 135…  Read More

Xelox as Effective as FOLFOX after Colorectal Cancer Progresses

XELOX, as second-line therapy, was found to be as effective as the more commonly used FOLFOX treatment for patients whose cancer had already gotten worse on treatment with Camptosar® (irinotecan). XELOX combines an oral drug Xeloda® (capecitabine) with Eloxatin® (oxaliplatin).  FOLFOX uses an infusional schedule of 5FU and leucovorin. Researchers randomly compared XELOX to FOLFOX4 to…  Read More